Highview Capital Management’s Edwards Lifesciences EW Stock Holding History

Highview Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$222K	Hold	2,775	–	–	0.08%	99
2025 Q4	$237K	Hold	2,775	–	–	0.08%	101
2025 Q3	$216K	Hold	2,775	–	–	0.08%	105
2025 Q2	$217K	Sell	2,775 -5,250	-65%	-$392K	0.08%	106
2025 Q1	$582K	Hold	8,025	–	–	0.24%	73
2024 Q4	$594K	Hold	8,025	–	–	0.23%	82
2024 Q3	$530K	Hold	8,025	–	–	0.22%	83
2024 Q2	$741K	Hold	8,025	–	–	0.31%	81
2024 Q1	$767K	Hold	8,025	–	–	0.34%	76
2023 Q4	$612K	Hold	8,025	–	–	0.33%	71
2023 Q3	$556K	Hold	8,025	–	–	0.32%	75
2023 Q2	$757K	Hold	8,025	–	–	0.41%	67
2023 Q1	$664K	Hold	8,025	–	–	0.38%	63
2022 Q4	$599K	Hold	8,025	–	–	0.36%	70
2022 Q3	$663K	Sell	8,025 -264	-3%	-$25.4K	0.49%	54
2022 Q2	$788K	Buy	8,289 +264	+3%	+$27.3K	0.61%	50
2022 Q1	$945K	Hold	8,025	–	–	0.61%	50
2021 Q4	$1.04M	Buy	+8,025	New	+$936K	0.67%	49

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Highview Capital Management's EW Position: Q1 2026 in Review

Highview Capital Management held its Edwards Lifesciences (EW) position steady in Q1 2026 at 2,775 shares worth $222K. The position accounts for 0.08% of the portfolio, ranked #99.

Highview Capital Management first reported a position in EW in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.04M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Highview Capital Management held 2,775 shares of Edwards Lifesciences worth $222K as of Q1 2026.
Highview Capital Management left its Edwards Lifesciences share count unchanged in Q1 2026.
Edwards Lifesciences made up 0.08% of Highview Capital Management's portfolio in Q1 2026, its #99 holding.
Highview Capital Management first reported a position in Edwards Lifesciences in Q4 2021 and has held it in 18 quarters since.
Highview Capital Management's Edwards Lifesciences position peaked at $1.04M in Q4 2021.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Highview Capital Management's 13F filing for Q1 2026, filed 8 May 2026.